OccuRx is a Melbourne-based biopharmaceutical firm founded in 2014 with investments from the Medical Research Commercialisation Fund, Brandon Capital Partners, and Uniseed. Specializing in the Biopharma and Biotechnology industries, the company is dedicated to developing groundbreaking therapeutic strategies for addressing ophthalmic disorders related to retinal fibrosis. Their most recent $1.50M grant investment from Brandon BioCatalyst on September 9, 2022 underscores the continued confidence and support from the investment community in OccuRx's pioneering work in the field of ophthalmology.
General Information
Get notified when OccuRx moves
Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.
Discover More
Australia Market
Biopharma
About OccuRx
Funding Rounds & Investors (4)
View All| Funding Stage | Amount | Investors | Lead Investors | Date |
|---|---|---|---|---|
| Series B | •••••• | 2 |
|
09 Sep 2022 |
| Grant | •••••• | 1 | •••• •••• | 20 Jul 2022 |
| Series A | •••••• | 2 |
|
15 Nov 2019 |
| Venture Round | •••••• | 3 |
|
18 May 2015 |
FAQ About OccuRx
We're actively collecting intelligence on OccuRx.
Track OccuRx to get notifiedDon't just browse. Track.
Signal Tracker monitors OccuRx and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.